administration route of glucagon

Glucagon Administration Routes and Product Attributes for Peptide Therapy Optimization

Abstract: Glucagon administration routes (intramuscular, subcutaneous, intranasal) critically impact peptide therapy optimization. Current market trends favor non-invasive delivery to enhance patient compliance. Comparative analysis reveals that intranasal glucagon offers superior onset speed but higher cost versus traditional injectables. Product attributes vary significantly in stability and bioavailability. Regulatory certifications (FDA, EMA) are essential for quality assurance. Industry data indicates a 7.2% CAGR for peptide therapeutics, driven by diabetes and obesity management. Selection criteria prioritize route-specific efficacy, cold-chain logistics compliance, and manufacturer GMP资质.